Title: Antimicrobial resistance of *Pasteurella multocida* isolated from diseased food-producing animals and pets

Clémence Bourély ^{1,2,3}, Géraldine Cazeau ², Eric Jouy ⁴, Marisa Haenni ⁵,
Jean-Yves Madec ⁵, Nathalie Jarrige ², Agnès Leblond ³, Emilie Gay ^{2*}

¹ École Nationale des Services Vétérinaires, VetAgro Sup, 69280 Marcy l’Étoile, France.

² Université de Lyon, ANSES, Laboratoire de Lyon, Unité Épidémiologie et appui à la surveillance, 31 avenue Tony Garnier, 69007 Lyon, France.

³ EPIA, UMR Epidémiologie des Maladies Animales et Zoonotiques, INRA, VetAgro Sup, Université de Lyon, 69280, Marcy L’Etoile, France

⁴ ANSES, Laboratoire de Ploufragan-Plouzané-Niort, Unité Mycoplasmodologie, Bactériologie et Antibiorésistance, Université Bretagne Loire, Technopôle Saint-Brieuc Armor, 22440 Ploufragan, France

⁵ Université de Lyon, ANSES, Laboratoire de Lyon, Unité Antibiorésistance et Virulence Bactériennes, 31 avenue Tony Garnier, Lyon 69007, France

* Corresponding author. E-mail: emilie.gay@anses.fr. Fax: +33 (0)478619145 Telephone: +33 (0)478726838

18 **Abstract**

19 Surveillance of *Pasteurella multocida* resistance in food-producing animals is essential to guide the
20 first-line treatment of respiratory diseases and to limit economic losses. Since *Pasteurella* are the
21 most common bacteria isolated from dog and cat bites, this surveillance is also needed to guide
22 treatment in humans in case of bites. The aim of this study was to characterize the phenotypic
23 resistance of *P. multocida* strains isolated from respiratory infections in animals, including both
24 food-producing animals and pets. Data collected between 2012 and 2017 by the French national
25 surveillance network for antimicrobial resistance referred to as RESAPATH were analyzed. The
26 proportions of resistance to antimicrobials of relevance in veterinary and human medicines were
27 estimated for each animal species. For cattle, resistance trends over the period were investigated
28 using non-linear analysis applied to time-series. In total, 5,356 *P. multocida* isolates were analyzed.
29 Proportions of resistance of *P. multocida* were almost all below 20% over the period, and, more
30 precisely, all resistance proportions were below 10% for rabbits, sheep and dogs. The highest
31 resistance proportions to enrofloxacin were identified for cattle (4.5%) and dogs (5.2%). Despite its
32 frequent use in livestock, resistance to florfenicol was less than 1% in *P. multocida* strains,
33 regardless of the animal species considered. Time series analyses revealed continuous increases in
34 resistance to tetracycline, tilmicosin, flumequine and fluoroquinolones in *P. multocida* strains
35 isolated from cattle. These trends contrast with the decrease in use of antibiotics in cattle in France
36 and with the decrease in resistance observed in *E. coli* isolated from diseased cattle.

37 **Keyword:** *Pasteurella multocida*; antimicrobial resistance; food-producing animal; dog; cat;
38 time series; RESAPATH

1. INTRODUCTION

Pasteurella multocida is a zoonotic bacterium that can infect a wide range of species, such as mammals and poultry. Humans are mainly contaminated by contact with animals, most often by bites, scratches or licking of abraded skin. They develop local inflammation of the soft tissues that can lead to bacteremia in severe cases (Wilson and Ho, 2013). In animals, *P. multocida* can cause primarily respiratory or systemic diseases (Harper and Boyce, 2017). Particularly in production animals such as cattle, swine and rabbits, *P. multocida* is a major cause of morbidity, leading to significant economic losses all over the world (Davies et al., 2003).

Antibiotics are the most used veterinary products for the management of *P. multocida* infections in animals. The main antibiotic classes approved for treatment of respiratory diseases include first-generation antibiotics, but also critically important antibiotics such as fluoroquinolones (Evira, 2018), which are also used in humans. Despite the frequent use of antibiotics to treat respiratory infections caused by *P. multocida* in animals, data on the epidemiology of its resistance are still rare. Studies have mainly focused to date on the genetic characterization of this bacterium, its phylogenetics, and its virulence (García-Alvarez et al., 2017; Massacci et al., 2018). In the past, *Pasteurella* resistances in animals have mainly been the subject of point-in-time research (Kaspar et al., 2007) or multiple year studies for example in Australia (Dayao et al., 2014), in China (Tang et al., 2009), or in Europe within the framework of European projects such as Vetpath (El Garch et al., 2016) and Compath (Morrissey et al., 2016).

However, regular monitoring of resistance levels of *P. multocida* strains isolated from animals is essential. Public health issues are to: (i) guide first-line treatment in animals and limit economic losses, (ii) guide treatment in humans in case of infection following exposure to an animal (before antibiogram results), and finally (iii) determine the scale of the phenomenon in order to guide control measures. The aim of this study was thus to characterize the epidemiology of phenotypic resistance of *P. multocida* strains isolated from respiratory infections in animals, including both food-producing animals and pets.

65 2. MATERIALS AND METHODS

66 2.1 Source of data

67 This study was performed using the dataset from RESAPATH, the well-established French
68 national surveillance network for antimicrobial resistance (AMR) in pathogenic bacteria from
69 animals. RESAPATH collects antibiogram results, through its member laboratories (74 out of 112
70 in the country in 2015 (Boireau et al., 2018a)) that are located in all the administrative regions of
71 France. All the antibiogram results collected by the RESAPATH are initially requested by
72 veterinarians in a context of disease for diagnostic purposes. Even if each laboratory has its own
73 strategy for bacterial identification, API galleries are often used and the biggest ones use Maldi-
74 TOF. All laboratories perform antibiograms by the disk diffusion method following the veterinary
75 recommendations of the Antibiogram Committee of the French Society of Microbiology (CA-SFM,
76 <https://www.sfm-microbiologie.org/>). Results are then compiled in the RESAPATH database and
77 duplicates were systematically traced and deleted.

78 From this database, data concerning *P. multocida* were extracted from 2012 to 2017. For
79 each animal species, in view of antibiotic use and practices depending on the pathological context
80 (Bourély et al., 2018), we specifically extracted data regarding respiratory disease, which is the
81 major disease caused by *P. multocida*. For duck isolates, septicemia was also considered because
82 extremely acute cases in ducks can include non-specific lesions of sepsis. Samples transmitted
83 initially to laboratories included nasal, tracheal or bronchial swabs, trans-tracheal aspirations and
84 lung tissues. Appropriate antibiotics of relevance in veterinary and human medicine were selected
85 for analysis, according to their spectrum of activity, their use to treat animals, and their public
86 health interest (Table 1).

87 2.2 Data analysis

88 Analyses were performed for animal species for which at least one hundred isolates of *P.*
89 *multocida* were collected over the period 2012-2017 (Supplementary Data). The first step in the

analysis was to categorize isolates as susceptible, intermediate or resistant, using their inhibition zone diameters compared with the breakpoints recommended by the veterinary section of the CASFM. From an epidemiological point of view, the event of interest is the non-susceptibility to a particular antibiotic, indicating that the isolate is no longer a wild-type strain. Therefore, intermediate isolates were grouped together with resistant isolates in the non-susceptible population, referred to as resistant in this study. For each animal species and antibiotic combination, the indicator of resistance was defined as the ratio between the number of resistant strains and the total number of strains collected. The resistance proportions were calculated over the whole period and their confidence intervals (CIs) were calculated using the exact binomial method. Proportions were then compared using Fisher's exact test.

Secondly, to detect variations in proportions over time, time-series analyses were performed for animal species/antibiotic combinations for which we had sufficient data, i.e. at least 25 antibiograms per time step (Barlow, 2011). To capture trends, we used generalized additive models (GAM), which are flexible and effective techniques for conducting nonlinear regression analysis in time-series studies. The proportion between the number of resistant strains and the total number of strains collected on a three-monthly time step was modelled using binomial regression. The analysis was carried out as described in Boireau et al. (2018b). R, version 3.5.0 was used for all statistical analyses (gam4 package for GAM implementation). We considered a p -value of ≤ 0.05 as a statistically significant difference. If trend variations were not significant, the trend was stationary.

3. RESULTS

In total, 5,356 *P. multocida* isolates collected between January 2012 and December 2017 were analyzed (Table 2). The proportions of resistance of *P. multocida* isolated from animals were almost all below 20% over the period, and, more precisely, all resistance proportions were below 10% for rabbits, sheep, and dogs.

The proportions of resistance to amoxicillin of *P. multocida* isolated from animals were all below 5% over the whole period. *P. multocida* isolates from rabbits presented the lower proportion

116 of resistance to gentamicin (1.8% [1.0; 3.0]) compared with isolates from other animal species
117 ($p<0.001$), except with isolates from swine ($p=0.1$). The proportion of resistance to tetracycline
118 varied greatly according to animal species and isolates from cattle presented the highest proportion
119 of resistance (23.4% [21.4; 25.5], $p<0.001$), followed by ducks (13.0% [10.1; 16.5], $p<0.01$),
120 whereas all other animal species presented resistance below 7%. Similarly, isolates from cattle
121 presented higher proportion of resistance to tilmicosin (17.2% [15.3; 19.2]) compared with isolates
122 from other animal species ($p<0.002$), except with isolates from cats ($p=0.1$) and resistance
123 proportions for other animal species were below 10%. By contrast, resistance proportions to
124 trimethoprim-sulfamethoxazole were below 10% for the majority of animal species including cattle
125 (6.2% [5.1; 7.4]). Resistance proportions to quinolones were above 10% only for isolates from
126 cattle (14.3% [12.2; 16.6]) and ducks (26.1% [22.1; 30.4]), and ducks presented the highest
127 resistance proportion ($p<0.001$). Resistance proportions to enrofloxacin were very low for swine
128 (0.5% [0.1; 1.3]) and rabbits (0.2% [0.0; 0.8]); though low, they were higher ($p<0.01$) for cats
129 (2.6% [1.6; 4.1]), ducks (3.7% [2.1; 5.8]), cattle (4.5% [3.5; 5.6]) and dogs (5.2% [3.1; 8.1]).
130 Resistance to florfenicol was close to zero for all animal species, without differences among them
131 ($p=0.6$).

132 From 2012 to 2017, most resistance trends of *P. multocida* isolated from cattle presented
133 significant variations over time. However, resistance trends to trimethoprim-sulfamethoxazole
134 ($p=0.9$), amoxicillin ($p=0.08$), and florfenicol ($p=0.9$) were stationary (Figure 1). Resistance trends
135 to tetracycline ($p>0.001$), tilmicosin ($p>0.001$), flumequine ($p=0.003$), and enrofloxacin ($p=0.008$)
136 increased continuously over the period. More specifically, resistance proportions to tetracycline,
137 tilmicosin and flumequine varied greatly from 2012 to 2017: they were below 15% at the beginning
138 of the period and reached 33.8% [27.0; 40.5], 26.5% [22.2; 30.8] and 21.0% [15.6; 26.4] in
139 December 2017, respectively. Resistance proportions to enrofloxacin increased from 2.0% [0.7; 3.4]
140 in January 2012 up to 7.3% [4.6; 10.0] in December 2017.

141 4. DISCUSSION

142 Data on the epidemiology of resistance of *P. multocida* isolates are rare. In these studies, the
143 samples size is very often low and/or the isolates of several animal species are grouped together
144 (Schwarz et al., 2007; Cucco et al., 2017), limiting interpretation by animal species. In Germany, a
145 study on 1,111 *P. multocida* isolated from swine reported similar resistance proportions to ours for
146 enrofloxacin and florfenicol (below 1%), for resistance to trimethoprim-sulfamethoxazole (between
147 4% and 10%) and to tetracycline (between 11.5% and 19.2%) (Kaspar et al., 2007). In Australia, a
148 more recent study on 51 *P. multocida* isolated from swine reported very low levels of resistance,
149 except for tetracycline (28%) (Dayao et al., 2014). Two studies in swine, one in China on 233
150 isolates and the other on 454 isolates collected in South Korea also identified high levels of
151 tetracycline resistance (58.0% and 66.5% respectively) (Tang et al., 2009; Oh et al., 2018), higher
152 than those reported in Europe (El Garch et al., 2016), North America (Sweeney, 2017), Australia
153 (Dayao et al., 2014) and in our study (6.7%). Similarly, resistance to florfenicol reached 18.5% in
154 South Korea, whereas it appeared to be very limited in Europe. These differences are likely the
155 result of differing in practices since antibiotic use is considered higher in Korea (Oh et al., 2018).

156 For rabbits, our results are consistent with a previous study conducted in Brazil on 45
157 commensal *P. multocida* isolates, which reported low or no resistance to beta-lactam,
158 fluoroquinolones, florfenicol, and tetracyclines (Ferreira et al., 2016).

159 A study in Europe on 134 *P. multocida* isolated from cattle between 2009 and 2012 already
160 reported that resistance to tetracycline (11.2%) was above other resistance (El Garch et al., 2016).
161 This estimate aligns with the resistance proportion calculated in our study in January 2012 from
162 cattle isolates (12.9% [8.1; 17.8]). The parallel increases of resistance proportions to different
163 antibiotics in *P. multocida* isolated from cattle suggest the joint spread of resistance determinants.
164 *P. multocida* can carry plasmids conferring resistance to different antibiotics: most commonly beta-
165 lactams, tetracycline, streptomycin and sulfonamides (Kadlec et al., 2011). Molecular investigations
166 are needed to confirm this hypothesis. Finally, these increasing resistance trends in *P. multocida*

isolates from cattle contrast with the stationary or decreasing resistance trends of *Escherichia coli* isolated from cattle in recent years (Boireau et al., 2018b).

4.1 Analysis in relation to antibiotic use

The differences observed between resistance proportions among animal species were probably due to differences in antibiotic use. For example, gentamicin is generally not used in rabbits due to its nephrotoxicity and the resistance to gentamicin was lower for this species. Besides, some insignificant differences between proportions were likely due to a lack of statistical power, related to a low number of isolates collected for some animals.

Due to a lack of specific data regarding antibiotic use in animals to treat *P. multocida* infections, resistance trends could not be directly analyzed in terms of antibiotic use in the models. Based on antibiotic sales for use in cattle (all diseases combined), exposure to antibiotics has decreased overall between 2011 and 2017 (-23%, all antibiotics considered) and exposure to fluoroquinolones has been decreasing since 2013 (-93%) (Anses-ANMV, 2018). However, several resistance trends in *P. multocida* isolates, including resistance trend to fluoroquinolones, increased from 2012 to 2017 in our study. These differences emphasize the importance of monitoring antibiotic use by animal species and by disease, to better document the use-resistance pattern.

Despite the frequent use of florfenicol in food-producing animals since its first usage in 1995 in France, resistance of *P. multocida* to florfenicol was below 1%, regardless of the animal species considered. However, a recent study reported that gastro-intestinal exposure of the microbiota to florfenicol leads to resistance selection in commensal *E. coli* (De Smet et al., 2018). These results underscore the importance of always using antibiotics prudently, and of continued monitoring of changes in resistance in bacteria, whether commensal or pathogenic.

4.2 Limitations

The major strength of our study was the availability of data regarding the susceptibility of *P. multocida* from an ongoing nationwide surveillance system for AMR in animals. Nevertheless, this study had several limitations due to potential selection bias, because laboratories join the

193 RESAPATH on a voluntary basis and antibiograms rely on decisions taken by veterinarians during
194 their veterinary practice. Because RESAPATH laboratories performed antibiograms by disk
195 diffusion, which is a qualitative method, no information regarding the minimal inhibitory
196 concentrations is collected. Despite a good standardization, isolates could be misclassified because
197 this method remains manual. Nevertheless, the annual participation of laboratories to quality
198 assurance proficiency tests contributes to control data and limit such misclassifications. The
199 proportions of samples from previously untreated compared to treated animals were unknown and
200 could potentially impact the resistance results. In addition, it was not possible to differentiate first
201 and subsequent sample submissions and we simply assumed that multiple sampling from the same
202 animal did not occur frequently considering the cost of the analysis. All these biases can lead to a
203 lack of representativeness and a misestimation of resistance levels. However if biases do not vary
204 over time, the observed resistance trends remain meaningful. A recent assessment of the
205 RESAPATH network concluded that the antibiograms collected were representative of the
206 antibiograms performed in animals in France (Boireau et al., 2018a).

207 **4.3 Public health issues**

208 *P. multocida* is the main bacterial species responsible for pasteurellosis in humans,
209 especially in cases of severe infections. In almost all reported cases, evidence of upstream contact
210 with an animal was mentioned (Wilson and Ho, 2013). Zoonotic transmission to humans usually
211 occurs through domestic animal bites, which can lead to significant morbidity and often require
212 specialized care and specific antibiotic treatments (Bula-Rudas and Olcott, 2018). Although bites
213 are often polymicrobial, *Pasteurellae*, and particularly *P. multocida*, are the most commonly
214 isolated bacteria from dog and cat bites (Freshwater, 2008). Since the 1950s, penicillins have
215 generally been used as empirical treatments of cat and dog bites, before antibiogram results are
216 obtained (Freshwater, 2008). According to the results of our study, given the low resistance of *P.*
217 *multocida* isolates from dogs and cats to penicillins, the use of these antibiotics is still a valid
218 therapeutic option.

219 **5. CONCLUSION**

220 This study provides an overall view of the antimicrobial resistance epidemiology of
221 *Pasteurella multocida* strains isolated from food-producing animals and pets in a context of
222 respiratory disease in France. It highlighted that resistance to florfenicol was very low for all
223 species. Time series analyses revealed continuous increases in resistance to tetracycline, tilmicosin,
224 and flumequine in *P. multocida* strains isolated from cattle, whereas the overall use of antibiotics in
225 cattle decreased over this same period in France. Furthermore, these trends contrast with decreasing
226 resistance trends of *E. coli* strains isolated from cattle in recent years. These differences likely
227 reflect differing practices according to the pathological contexts, stressing the importance of
228 monitoring bacteria other than *E. coli*, which is commonly monitored. Since *Pasteurellae* are the
229 most common bacteria isolated from dog and cat bites in humans, these results are also useful in
230 guiding the therapeutic choices of physicians in case of bite wounds or scratches.

231 **Funding**

232 This work was partly supported by the French Ministry of Agriculture (<http://agriculture.gouv.fr>).
233 No additional external funding was received for this study. The funders had no role in study design,
234 data collection, and analysis, decision to publish, or preparation of the manuscript.

235 **Conflicts of interest**

236 The authors declare no potential conflicts of interest with respect to the research, authorship, and/or
237 publication of this article.

238 **Data availability**

239 The data used for this study was obtained from the RESAPATH network and the access to data is
240 controlled by the French Agency for Food, Environmental and Occupational Health & Safety
241 (ANSES). Conditions of approval (respecting the anonymity of farms and laboratories) do not allow
242 us to distribute or make available data directly to other parties.

243 **Author contributions**

244 All the authors read and approved the final manuscript.

245 **Acknowledgements**

246 The authors would like to thank all the voluntary laboratories that collected and transmitted
247 antibiogram results to RESAPATH over several years. The authors are particularly grateful to
248 Christelle Philippon (RESAPATH's secretary) for her meticulous follow-up of laboratories and
249 careful data collection, and Jean-Luc Vinard (RESAPATH's data architect) for his careful
250 management of the database.

251 **References**

- 252 Anses-ANMV, 2018. Suivi des ventes de médicaments vétérinaires contenant des antibiotiques en
253 France en 2017 (Rapport annuel). Anses.
- 254 Barlow, J., 2011. Mastitis therapy and antimicrobial susceptibility: a multispecies review with a
255 focus on antibiotic treatment of mastitis in dairy cattle. *J. Mammary Gland Biol. Neoplasia*
256 16, 383–407. doi:10.1007/s10911-011-9235-z
- 257 Boireau, C., Jarrige, N., Cazeau, G., Jouy, É., Haenni, M., Philippon, C., Calavas, D., Madec, J.-Y.,
258 Leblond, A., Gay, E., 2018a. Représentativité et couverture du résapath, le réseau
259 d'épidémiosurveillance de l'antibiorésistance des bactéries pathogènes animales. *Bull.*
260 *Épidémiologique Santé Anim. Aliment.* 80, 10–14.

261 Boireau, C., Morignat, É., Cazeau, G., Jarrige, N., Jouy, É., Haenni, M., Madec, J.-Y., Leblond, A.,
262 Gay, É., 2018b. Antimicrobial resistance trends in *Escherichia coli* isolated from diseased
263 food-producing animals in France: A 14-year period time-series study. *Zoonoses Public*
264 *Health* 65, 86–94. doi:10.1111/zph.12412

265 Bourély, C., Fortané, N., Calavas, D., Leblond, A., Gay, É., 2018. Why do veterinarians ask for
266 antimicrobial susceptibility testing? A qualitative study exploring determinants and
267 evaluating the impact of antibiotic reduction policy. *Prev. Vet. Med.* 159, 123–134.
268 doi:10.1016/j.prevetmed.2018.09.009

269 Bula-Rudas, F.J., Olcott, J.L., 2018. Human and animal bites. *Pediatr. Rev.* 39, 490–500.
270 doi:10.1542/pir.2017-0212

271 Cucco, L., Massacci, F.R., Sebastiani, C., Mangili, P., Bano, L., Cocchi, M., Luppi, A., Ortenzi, R.,
272 Pezzotti, G., Magistrali, C.F., 2017. Molecular characterization and antimicrobial
273 susceptibility of *Pasteurella multocida* strains isolated from hosts affected by various
274 diseases in Italy. *Vet. Ital.* 53, 21–27. doi:10.12834/VetIt.661.3256.2

275 Davies, R.L., Mac Corquodale, R., Baillie, S., Caffrey, B., 2003. Characterization and comparison
276 of *Pasteurella multocida* strains associated with porcine pneumonia and atrophic rhinitis. *J.*
277 *Med. Microbiol.* 52, 59–67. doi:10.1099/jmm.0.05019-0

278 Dayao, D.A.E., Gibson, J.S., Blackall, P.J., Turni, C., 2014. Antimicrobial resistance in bacteria
279 associated with porcine respiratory disease in Australia. *Vet. Microbiol.* 171, 232–235.
280 doi:10.1016/j.vetmic.2014.03.014

281 De Smet, J., Boyen, F., Croubels, S., Rasschaert, G., Haesebrouck, F., De Backer, P., Devreese, M.,
282 2018. Similar gastro-intestinal exposure to florfenicol after oral or intramuscular
283 administration in pigs, leading to resistance selection in commensal *Escherichia coli*. *Front.*
284 *Pharmacol.* 9, 1265. doi:10.3389/fphar.2018.01265

285 El Garch, F., de Jong, A., Simjee, S., Moyaert, H., Klein, U., Ludwig, C., Marion, H., Haag-
286 Diergarten, S., Richard-Mazet, A., Thomas, V., Siegwart, E., 2016. Monitoring of

287 antimicrobial susceptibility of respiratory tract pathogens isolated from diseased cattle and
 288 pigs across Europe, 2009-2012: VetPath results. Vet. Microbiol. 194, 11–22.
 289 doi:10.1016/j.vetmic.2016.04.009

290 Evira, 2018. Recommendations for the use of antimicrobials in the treatment of the most significant
 291 infectious and contagious diseases in animals. University of Helsinki Faculty of veterinary
 292 medicine.

293 Ferreira, T.S.P., Moreno, L.Z., Felizardo, M.R., de Gobbi, D.D.S., Filsner, P.H. de L.N., de Moura
 294 Gomes, V.T., Moreno, M., Moreno, A.M., 2016. Pheno- and genotypic characterization of
 295 *Pasteurella multocida* isolated from cats, dogs and rabbits from Brazil. Comp. Immunol.
 296 Microbiol. Infect. Dis. 45, 48–52. doi:10.1016/j.cimid.2016.02.004

297 Freshwater, A., 2008. Why your housecat's trite little bite could Cause you quite a fright: a study of
 298 domestic felines on the occurrence and antibiotic susceptibility of *Pasteurella multocida*.
 299 Zoonoses Public Health 55, 507–513. doi:10.1111/j.1863-2378.2008.01152.x

300 García-Alvarez, A., Vela, A.I., San Martín, E., Chaves, F., Fernández-Garayzábal, J.F., Lucas, D.,
 301 Cid, D., 2017. Characterization of *Pasteurella multocida* associated with ovine pneumonia
 302 using multi-locus sequence typing (MLST) and virulence-associated gene profile analysis
 303 and comparison with porcine isolates. Vet. Microbiol. 204, 180–187.
 304 doi:10.1016/j.vetmic.2017.04.015

305 Harper, M., Boyce, J.D., 2017. The myriad properties of *Pasteurella multocida* lipopolysaccharide.
 306 Toxins 9. doi:10.3390/toxins9080254

307 Kadlec, K., Brenner Michael, G., Sweeney, M.T., Brzuszkiewicz, E., Liesegang, H., Daniel, R.,
 308 Watts, J.L., Schwarz, S., 2011. Molecular basis of macrolide, triamylide, and lincosamide
 309 resistance in *Pasteurella multocida* from bovine respiratory disease. Antimicrob. Agents
 310 Chemother. 55, 2475–2477. doi:10.1128/AAC.00092-11

311 Kaspar, H., Schröder, U., Wallmann, J., 2007. Quantitative resistance level (MIC) of *Pasteurella*
312 *multocida* isolated from pigs between 2004 and 2006: national resistance monitoring by the
313 BVL. Berl. Munch. Tierarztl. Wochenschr. 120, 442–451.

314 Massacci, F.R., Magistrali, C.F., Cucco, L., Curcio, L., Bano, L., Mangili, P., Scoccia, E., Bisgaard,
315 M., Aalbæk, B., Christensen, H., 2018. Characterization of *Pasteurella multocida* involved
316 in rabbit infections. Vet. Microbiol. 213, 66–72. doi:10.1016/j.vetmic.2017.11.023

317 Morrissey, I., Moyaert, H., de Jong, A., El Garch, F., Klein, U., Ludwig, C., Thiry, J., Youala, M.,
318 2016. Antimicrobial susceptibility monitoring of bacterial pathogens isolated from
319 respiratory tract infections in dogs and cats across Europe: ComPath results. Vet. Microbiol.
320 191, 44–51. doi:10.1016/j.vetmic.2016.05.020

321 Oh, Y.-H., Moon, D.-C., Lee, Y.J., Hyun, B.-H., Lim, S.-K., 2018. Antimicrobial resistance of
322 *Pasteurella multocida* strains isolated from pigs between 2010 and 2016. Vet. Rec. Open 5,
323 e000293. doi:10.1136/vetreco-2018-000293

324 Schwarz, S., Alesík, E., Grobbel, M., Lübke-Becker, A., Werckenthin, C., Wieler, L.H., Wallmann,
325 J., 2007. Antimicrobial susceptibility of *Pasteurella multocida* and *Bordetella*
326 *bronchiseptica* from dogs and cats as determined in the BfT-GermVet monitoring program
327 2004-2006. Berl. Munch. Tierarztl. Wochenschr. 120, 423–430.

328 Sweeney, M.T., 2017. Antimicrobial susceptibility of *Actinobacillus pleuropneumoniae*,
329 *Pasteurella multocida*, *Streptococcus suis*, and *Bordetella bronchiseptica* isolated from pigs
330 in the United States and Canada, 2011 to 2015. J. Swine Health Prod. 25, 106–120.

331 Tang, X., Zhao, Z., Hu, J., Wu, B., Cai, X., He, Q., Chen, H., 2009. Isolation, antimicrobial
332 resistance, and virulence genes of *Pasteurella multocida* strains from swine in China. J.
333 Clin. Microbiol. 47, 951–958. doi:10.1128/JCM.02029-08

334 Wilson, B.A., Ho, M., 2013. *Pasteurella multocida*: from zoonosis to cellular microbiology. Clin.
335 Microbiol. Rev. 26, 631–655. doi:10.1128/CMR.00024-13

336

337 **Tables**

338 **Table 1.** Selected antibiotics and the corresponding antibiotic classes

339 **Table 2.** Antimicrobial resistance (in % with 95% CI) in *P. multocida* isolated from diseased food-
340 producing animals and pets in a context of respiratory disease in France over the 2012- 2017 period

341 **Figure**

342 **Figure 1.** Trends for antimicrobial resistance in *P. multocida* isolates from cattle with respiratory
343 diseases over the period 2012-2017, on a three-monthly time scale (at least 25 isolates per time
344 step)

Table 1. Selected antibiotics and the corresponding antibiotic classes

Antibiotic classes	Antibiotics
Beta-lactams	Amoxicillin
Aminoglycosides	Gentamicin
Tetracyclines	Tetracycline
Folate pathway inhibitors	Trimethoprim-sulfamethoxazole
Phenicol	Florfenicol
Macrolides	Tilmicosin
Quinolones	Nalidixic acid/Flumequine
Fluoroquinolones	Enrofloxacin

Table 2. Antimicrobial resistance (in % with 95% CI) in *P. multocida* isolated from diseased food-producing animals and pets in a context of respiratory disease in France over the 2012-2017 period

Antibiotic		Cat	Dog	Cattle	Duck ²	Sheep	Swine	Rabbit
Amoxicillin	Number of isolates	657	325	1,635	464	302	796	224
	Proportion	4.1 [2.7; 5.9]	4.9 [2.8; 7.9]	2.3 [1.6; 3.1]	0.9 [0.2; 2.2]	2.3 [0.9; 4.7]	0.3 [0.0; 0.9]	1.3 [0.3; 3.9]
Gentamicin	Number of isolates	690	352	1,511	Not-tested	300	458	789
	Proportion	9.3 [7.2; 11.7]	6.0 [3.7; 9.0]	4.6 [3.6; 5.8]		6.7 [4.1; 10.1]	3.5 [2.0; 5.6]	1.8 [1.0; 3.0]
Tetracycline	Number of isolates	440	192	1,702	460	311	784	935
	Proportion	4.1 [2.4; 6.4]	4.2 [1.8; 8.0]	23.4 [21.4; 25.5]	13.0 [10.1; 16.5]	4.5 [2.5; 7.4]	6.7 [5.1; 8.7]	3.5 [2.4; 4.9]
Trimethoprim-sulfamethoxazole	Number of isolates	679	345	1,705	465	311	839	935
	Proportion	13.0 [10.5; 15.7]	7.5 [5.0; 10.8]	6.2 [5.1; 7.4]	11.4 [8.7; 14.6]	7.1 [4.5; 10.5]	15.4 [13.0; 18.0]	3.2 [2.2; 4.5]
Florfenicol	Number of isolates	206	85	1,695	371	298	811	327
	Proportion	0.5 [0.0; 2.7]	0.0 [0.0; 4.2]	0.4 [0.2; 0.8]	0.3 [0.0; 1.5]	0.0 [0.0; 1.2]	0.8 [0.3; 1.6]	0.0 [0.0; 1.1]
Tilmicosin	Number of isolates	54	Not-tested	1470	447	193	795	876
	Proportion	7.4 [2.1; 17.9]		17.2 [15.3; 19.2]	0.9 [0.2; 2.3]	7.3 [4.0; 11.9]	2.1 [1.3; 3.4]	5.1 [3.8; 6.8]
Nalidixic acid / Flumequine ¹	Number of isolates	531	253	1,014	449	257	522	494
	Proportion	3.6 [2.2; 5.5]	8.7 [5.5; 12.9]	14.3 [12.2; 16.6]	26.1 [22.1; 30.4]	2.7 [1.1; 5.5]	2.7 [1.5; 4.5]	6.9 [4.8; 9.5]
Enrofloxacin	Number of isolates	685	347	1,672	465	294	780	906
	Proportion	2.6 [1.6; 4.1]	5.2 [3.1; 8.1]	4.5 [3.5; 5.6]	3.7 [2.1; 5.8]	1.4 [0.4; 3.4]	0.5 [0.1; 1.3]	0.2 [0.0; 0.8]

¹ Nalidixic acid for dog, cat and sheep, flumequine otherwise

² In a context of respiratory disease and septicemia